Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT.
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT.
复制标题
使用 HER2 靶向 89Zr-帕妥珠单抗 PET/CT 鉴定 HER2 阴性原发性乳腺癌患者的 HER2 阳性转移灶。
DOI：
10.1148/radiol.2020192828
复制
发表时间：
2020
期刊：
影响因子：
19.7
通讯作者：
Lewis,JasonS
中科院分区：
文献类型：
--
作者：
Ulaner,GaryA;Carrasquillo,JorgeA;Riedl,ChristopherC;Yeh,Randy;Hatzoglou,Vaios;Ross,DaraS;Jhaveri,Komal;Chandarlapaty,Sarat;Hyman,DavidM;Zeglis,BrianM;Lyashchenko,SergeK;Lewis,JasonS
背景人表皮生长因子受体2（HER 2）靶向治疗是一种新的靶向治疗方法。 在HER 2阳性恶性肿瘤患者中成功;然而， HER 2表达的时间异质性可能会妨碍识别 目的确定是否使用HER 2靶向PET示踪剂锆 89（89 Zr）-帕妥珠单抗可以描述在肿瘤患者中的HER 2阳性转移。 材料和方法2019年1月至6月，在2019年1月至6月期间， 乳腺癌和活检证实的转移性疾病入选了一个 前瞻性临床试验（ClinicalTrials.govNCT02286843）和用于非侵入性整体活检的89 Zr-帕妥珠单抗PET/CT 评估潜在的HER 2阳性转移。可疑的89 Zr-帕妥珠单抗-avid病灶 对HER 2阳性转移灶进行组织取样并通过病理学检查。 结果24名女性（平均年龄，55岁± 11岁[标准差]） HER 2阴性原发性乳腺癌患者。六名妇女 在89 Zr-帕妥珠单抗PET/CT上显示病灶， 怀疑是HER 2阳性疾病在这六名妇女中，有三名 活检证实HER 2阳性转移，2例病理结果 证实HER 2阴性疾病，一个有细针抽吸 结论人表皮生长因子受体2（HER 2）靶向显像与 锆89-帕妥珠单抗PET/CT成功检测到 HER 2阴性原发性乳腺癌女性中的HER 2阳性转移 癌这证明了靶向成像识别 患者进行靶向治疗，否则可能不会 © RSNA，2020参见Mankoff和Pantel在本期的社论。
BackgroundHuman epidermal growth factor receptor 2 (HER2)-targeted therapies are successful in patients with HER2-positive malignancies; however, spatial and temporal heterogeneity of HER2 expression may prevent identification of optimal patients for these therapies.PurposeTo determine whether imaging with the HER2-targeted PET tracer zirconium 89 (89Zr)-pertuzumab can depict HER2-positive metastases in women with HER2-negative primary breast cancer.Materials and MethodsFrom January to June 2019, women with biopsy-proven HER2-negative primary breast cancer and biopsy-proven metastatic disease were enrolled in a prospective clinical trial (ClinicalTrials.govNCT02286843) and underwent89Zr-pertuzumab PET/CT for noninvasive whole-biopsy evaluation of potential HER2-positive metastases.89Zr-pertuzumab–avid foci that were suspicious for HER2-positive metastases were tissue sampled and examined by pathologic analysis to document HER2 status.ResultsTwenty-four women (mean age, 55 years ± 11 [standard deviation]) with HER2-negative primary breast cancer were enrolled. Six women demonstrated foci at89Zr-pertuzumab PET/CT that were suspicious for HER2-positive disease. Of these six women, three had biopsy-proven HER2-positive metastases, two had pathologic findings that demonstrated HER2-negative disease, and one had a fine-needle aspirate with inconclusive results.ConclusionHuman epidermal growth factor receptor 2 (HER2)-targeted imaging with zirconium 89–pertuzumab PET/CT was successful in detecting HER2-positive metastases in women with HER2-negative primary breast cancer. This demonstrates the ability of targeted imaging to identify patients for targeted therapies that might not otherwise be considered.© RSNA, 2020See the editorial by Mankoff and Pantel in this issue.